Skip to Main Content

Prelude Therapeutics Incorporated

PRLD Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
PRLD Income Statement
PRLD Balance Sheet
PRLD Cash Flow

Recent trades of PRLD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
PRLD Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
PRLD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
PRLD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by PRLD's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Oct. 29, 2024
  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Mar. 26, 2024
  • Patent Title: Brm targeting compounds and associated methods of use Jul. 18, 2023
  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Jun. 27, 2023
  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Jun. 13, 2023
  • Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (prmt5) Dec. 13, 2022
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Feb. 22, 2022
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jan. 11, 2022
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jan. 04, 2022
  • Patent Title: Selective inhibitors of protein arginine methytransterase 5 (prmt5) Dec. 28, 2021
  • Patent Title: Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein Sep. 28, 2021
  • Patent Title: Selective inhibitors of protein arginine methlytransferase 5 (prmt5) Aug. 03, 2021
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jul. 14, 2020
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Feb. 25, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of PRLD in WallStreetBets Daily Discussion

PRLD News

Recent insights relating to PRLD

CNBC Recommendations

Recent picks made for PRLD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PRLD

PRLD Top Shareholders
Shareholder
Shares Held
PRLD Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

PRLD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view PRLD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top